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Abstract
Glycomic profiling of tumour tissues consistently shows alterations in N- and 
O-glycosylation profiles of glycoproteins and glycolipids compared to healthy tissues, 
with important functional implications for cancer cell biology. The overexpression of 
tumour-associated carbohydrate antigens (TACAs), as a result of aberrant glycosylation 
in tumours, is usually correlated with poor prognosis and survival of cancer patients. In 
tumours, TACAs are associated with worse tumour progression than the deletion and 
inactivation of tumour suppressor genes. The findings of TACAs acting are not merely 
tumour markers but also constitute part of the machinery in inducing cancer metastasis 
and invasiveness further strengthen the scientific rationales for immunotherapy targeting 
TACAs. Despite the attractiveness of the TACAs, there are very few anti-glycan monoclo-
nal antibodies (mAbs), as glycans usually induce low-affinity IgM responses. This chap-
ter provides an overview of TACAs, direct killing anti-glycan mAbs, and introduces two 
murine mAbs (FG88 mAbs) that recognise Lewis carbohydrate antigens overexpressed 
on tumour glycoconjugates with high functional affinity. Although the production of 
anti-glycan mAbs against cancers is not new, the production of high-affinity IgG anti-
glycan mAbs is novel. FG88 mAbs definitely have great potential in cancer therapy and 
serve as valuable tools in glycobiology research.
Keywords: cancer, Lewis carbohydrate antigen, therapeutic monoclonal antibody, 
oncosis, antibody drug conjugate
1. Introduction
Cell surface glycosylation is a post-translational modification of proteins and lipids, which 
is universal to all living cells and plays an important role in cell signalling, immune recogni-
tion and cell-cell interactions [1]. Monosaccharide units serve as building blocks of glycans 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestric ed use,
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(polysaccharides) that are synthesised by a complex series of post-translational enzymatic 
steps [1, 2]. There are several main families of glycoconjugates: (1) the Asn-linked (N-linked) 
and Ser-/Thr-linked (O-linked) oligosaccharides that are present on many glycoproteins, 
(2) the glycosaminoglycans (GAGs) either as linear-free polysaccharides (such as hyaluro-
nan) or attached to serine residues of proteoglycans (such as heparin sulphate and chondroi-
tin sulphate), (3) the sphingolipids that consist of oligosaccharides linked to ceramide and 
(4) the glycosylphosphatidylinositol (GPI)-linked proteins, which are proteins that express a 
glycan chain linked to phosphatidylinositol [2, 3] (Figure 1).
2. Glycoproteins
It has been appreciated for some time that protein glycosylation is the most complicated post-
translational modification that a protein can undergo [4]. Protein glycosylation is important 
as it alters the behaviour of proteins, making them more soluble, protecting them from pro-
teolysis, covering antigenic sites and altering the orientation of proteins on cell surfaces [5]. 
In glycoproteins, the carbohydrate units are linked to the protein backbone by N- and/or 
O-glycosidic bonds, C-mannosyl bonds, phosphoglycosyl bonds and glypiated linkage (GPI 
anchor) [4].
N-glycans are covalently attached to the asparagine (Asn) residues of proteins, and the con-
sensus sequence for N-glycosylation is Asn-X-Ser/Thr, where X can be any amino acid except 
proline. In O-glycosylation, the glycan is attached to the side chains of serine or threonine 
residues. Unlike N-linked glycosylation, no consensus sequence defining an O-linked glyco-
sylation site has been reported in Ref. [4]. C-mannosylation is a novel type of protein glyco-
sylation, which differs fundamentally from N- and O-glycosylations. It involves covalently 
Figure 1. Common glycoconjugates on human cells.
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attachment of an α-mannopyranosyl residue to the indole C2 carbon atom of tryptophan 
(Trp) via a C-C link [6, 7]. The phosphoglycosyl bond is another distinct type of glycopep-
tide linkage [N-acetylglucosamine (GlcNac), mannose (Man) and fucose (Fuc)] involving an 
attachment of a carbohydrate to protein via a phosphodiester bond [8]. Another important 
carbohydrate-protein connection is the GPI anchor. In this connection, mannose is linked 
to phosphoethanolamine, which in turn is attached to the terminal carboxyl group of the 
protein [9].
3. Glycolipids
Glycolipids constitute approximately 3% of the outer layer of the plasma membrane, and they 
are composed of a lipid tail and a carbohydrate head. Glycolipids are classified into three 
main groups, including glycoglycerolipids, glycosylphosphatidylinositols (GPI) and glyco-
sphingolipids (GSLs), based on the type of lipid component. Of these glycolipids, GSLs are 
the ones that are most widely overexpressed on tumours [10].
GSLs are ubiquitous membrane constituents, which are embedded in the cell plasma mem-
brane [11]. Ninety percent of mammalian GSL biosynthesis begins with the synthesis of glu-
cosylceramide (GlcCer), which is a key precursor of the glycosphingolipid series [12]. The 
process takes place on the cytosolic face of the Golgi complex via the action of the Type I trans-
membrane protein glucosylceramide (GlcCer) synthase [13], which transfers a glucose (Glu) 
residue to ceramide in the β-glycosidic linkage [14, 15]. Galactose is then added to GlcCer to 
generate lactosylceramide (LacCer) by β-1,4-galactosyltransferases in the lumen of the Golgi 
apparatus [10]. Further glycosylation steps are catalysed by different glycosyltransferases 
Figure 2. Synthetic pathways for the major GSL species. Lactosylceramide provides the branch point for different GSL 
series.
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with different specificities and result in the generation of more complex GSLs [16]. The major 
GSL series are defined by their internal core carbohydrate sequence. They are the ganglio-
series (galNacβ1-4 gal), globo-series (galα1-4 gal), lacto-series (galβ1-3glcNacβ1-3 gal) and 
neolacto-series (galβ1-4glcNacβ1-3 gal). LacCer provides the branch point for the synthesis of 
all these GSL series (Figure 2) [12].
4. Aberrant glycosylation in cancers
Aberrant glycosylation has been described as one of the hallmarks of cancer. Aberrant gly-
cosylation of proteins and lipids during malignant transformation leads to the overexpres-
sion of tumour-associated carbohydrate antigens (TACAs) [17]. Evidence is accumulating that 
TACAs have contributed to various aspects of cancer development and progression, including 
proliferation, invasion, angiogenesis and metastasis [2, 18]. Thus, studying the mechanisms 
and consequences of variations in glycosylation associated with cancers will provide crucial 
insight into cancer progression. Importantly, TACAs are overexpressed mostly on tumour cell 
surface, making them potential diagnostic markers and ideal therapeutic targets [19].
In general, aberrant glycosylation in cancers is due to the following changes: (1) under- or 
overexpression of glycosyltransferases, (2) altered expression of glycoconjugate acceptor [20], 
(3) altered sugar nucleotide transporter activity [21] and (4) improper function of the Golgi 
structure [22].
4.1. Altered glycosylation patterns in cancer
In cancers, the expression of glycosyltransferases is often deregulated. For example, 
N-acetylglucosaminyltransferase V (GnT-V), which catalyses the formation of β-1,6-GlcNAc 
branching structures, is expressed only at very low level in normal mammary gland. However, 
in cancer, the expression of GnT-V has been upregulated, resulting in highly branched 
N-glycan structures which were found to be associated with cancer growth and metastasis 
[20, 23–25]. Overexpression of beta-1,3-N-acetylglucosaminyltransferase 8 (β3GnT8) results in 
increased levels of polylactosamine structures in colorectal carcinoma [26], and upregulation 
of N-acetylglucosaminyltransferase III (GnT-III) increase bisected N-glycans in liver cancer 
[27, 28]. Aberrant expression of alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 
(ST6GalNAC-I) in breast cancer resulted in the sialylation of Tn antigen to form the sialyl-Tn 
(STn) antigen [29]. Altered expression of fucosyltransferases is responsible for the aberrant 
expression of Lewis carbohydrate antigens such as Lewis a (Lea), sialyl-Lewis a (SLea), Lewis 
x (Lex) and Sialyl-Lewis x (SLex) in many types of tumours [30–32].
Incomplete glycosylation is another abnormal feature found in human cancer. The expression 
of truncated O-glycans such as Tn, STn and T antigens had been reported in a wide range of 
tumours [33–36]. Incomplete glycosylation of these truncated glycans is due to the defects in 
the secretary pathway organelles (endoplasmic reticulum and Golgi) [33], the absence of gly-
cosyltransferases responsible for the generation of core glycan for chain elongation [37] and 
the overexpression of sialyltransferases responsible for the addition of terminal sialic acid 
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(i.e. conversion of Tn to STn antigen) [33, 38, 39]. For example, in neoplastic cells, alterations 
in glycosylation of O-linked glycans had been shown to affect oligomerisation of cell surface 
receptors, thus influencing the stimulation of these receptors. Wagner et al. demonstrated 
the inhibition of complex O-glycan formation (N-acetyl-galactosamine galactose core I struc-
ture and its subsequent sialylation), resulted in the impairment of death receptors 4 and 5 
(DR4 and DR5), which significantly impact the apoptotic pathway signalling by TNF-related 
apoptosis-inducing ligand (TRAIL) [40].
In addition, specific changes in O-glycan (GalNAc-Ser/Thr) and N-glycan core structures 
have been reported to lead to the generation of different core glycans with different degrees 
of glycan branching [27, 28], which in turn significantly impact the overall glycan structure 
and function.
4.2. Tumour-associated carbohydrate antigens (TACAs)
4.2.1. Altered sialic acid expression
As early as the 1960s, there was evidence that tumour cells of various origins increased the 
expression of sialic acids on membrane glycoproteins and glycolipids as well as their secre-
tion into the tumour microenvironment [41–43]. Sialic acids on normal cells are involved in 
multiple different physiologic processes [44]. However, hypersialylation of tumour cells spe-
cifically benefits tumour cell growth, promotes metastases [45, 46] and correlates with a poor 
prognosis of cancer patients [47].
Sialic acids are nine-carbon backbone α-ketoacidic sugars [3]. In general, sialic acids terminate 
the outer end of glycans (sialoglycans) via more than 20 distinct Golgi-resident sialyltransfer-
ases (ST). This enzymatic process is carried out via their second carbon (C2) to either galactose 
(α2-3Gal or α2-6Gal), N-acetylgalactosamine (α2-6GalNac) or another sialic acid (α2-8Sia) 
[48]. Altogether, the different linkages to underlying sugars result in a tremendous diversity 
of sialoglycans [44]. Sialoglycans are known to participate in cell-cell and cell-extracellular 
matrix interaction, including adhesion, migration and immune recognition [44]. Sialic acid-
binding immunoglobulin-like lectins (Siglecs) are receptor families that specifically recognise 
sialoglycans. Siglecs can be found on most immune cells, and they can transmit immuno-
suppressive signals upon binding to sialic acid ligands. Thus, increased expression of siglec 
ligands by tumour cells could contribute to tumour immune invasion [49].
There are a number of causes of the increase in cell surface sialic acid [50]. Changes to the 
core structures of N-glycans are one of the most common aberrant glycosylations in cancer. 
Increased activity of GNT-V (also known as MGAT5) was found to result in larger and more 
branched N-glycans, thus providing additional acceptors for terminal sialylation [20, 50]. 
Similarly, carcinomas that overproduce mucins (heavily glycosylated high-molecular-weight 
glycoproteins, e.g. MUCI and MUC4) which contain aberrant O-linked glycosylation can 
lead to increased sialylation [51, 52]. Together with increased expression of sialyltransferases 
[53], these enzymes increase cell surface sialylation and metastatic potential [20]. In addition, 
tumour cells often overexpress α2-6 sialic acid, mainly due to upregulation of the ST6Gal-I 
[54–56] or ST6GalNAc sialyltransferases [29, 57] that respectively conjugate terminal sialic 
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acid to N-glycans or O-glycans and glycolipids [53]. Mass spectrometry analysis of human 
serum sialo-glycoproteins revealed increased expression level of α2-6 sialylation in breast 
cancer [58] and lung cancer samples [59], whereas α2-3 sialylation was increased in prostate 
cancer samples [60], malignant brain tumours [61] and ovarian serous carcinomas [62].
Aberrant expression of sialic acids confers major advantages to tumour cells. Therefore, by 
targeting these, sialoglycans overexpressed on tumours may be highly beneficial.
4.2.2. Altered Lewis carbohydrate antigen expression
Lewis carbohydrate antigens can be found on various glycoconjugates in most human 
epithelial tissues [63]. They are formed by the sequential addition of fucose onto oligo-
saccharide precursor chains on glycoproteins or glycolipids through the action of a set of 
glycosyltransferases [64]. Lex was reported to be overexpressed in breast and gastrointes-
tinal carcinomas. Normal expression of Lex is restricted on certain normal epithelial cells 
including the oesophagus, stomach, small bowel, ciliated epithelium of trachea, bronchus 
[65, 66] and normal human polymorphonuclear neutrophils (PMNs) [67]. Ley was reported 
to be overexpressed on ovarian, breast, prostate, colon and lung carcinomas. Although Ley 
expression can be found on both normal and neoplastic tissues, Ley distribution differs 
between the two tissue types. Expression of Ley on normal epithelial tissues is restricted to 
the secretory borders of epithelial surfaces, making it less accessible to circulating antibod-
ies. Conversely, Ley expression on epithelial cancer cells occurs on all surfaces including 
luminal surfaces [65].
Sialylated Lewis carbohydrate antigens such as SLea and SLex are significantly enhanced in 
cancer [68, 69]. The expression of these cancer-associated antigens results mainly from the 
upregulation of sialyltransferases [68]. SLea is normally present on the inner surface of the 
ductal epithelium of a variety of epithelial tissues, which makes it largely inaccessible to anti-
bodies and immune effector cells [70]. SLex can be found on granulocytes, normal oral mucosa 
and breast tissue [71]. Both SLea and SLex are found to be aberrantly expressed on the surface 
of a broad range of carcinomas such as breast, ovarian, melanoma, colon, liver, lung and 
prostate [72]. Overexpression of SLex and SLea appears to directly correlate with increased 
metastatic disease and poorer overall survival in patients with colorectal cancer invasion [73]. 
Similar results were obtained from analysis the combination of SLea, SLex and Ley antigens in 
non-small-cell lung cancer (NSCLC) patients [74].
4.2.3. Altered ganglioside expression
Gangliosides are acidic glycosphingolipids with the presence of at least one sialic acid linked 
to their oligosaccharide chain [75]. Biosynthesis of gangliosides involves sequential addition 
of sialic acids to lactosylceramide (LacCer) by ST3Gal V (GM3 synthase), ST8Sial I (GD3 syn-
thase) and ST8Sia V (GT3 synthase) that leads to the generation of the a-, b-, and c-series gan-
glioside precursors, respectively, representing the mono-, di-, and tri-sialylated gangliosides 
(Figure 3) [68]. In general, gangliosides are involved in cell-cell recognition or regulation of 
downstream signalling of various proteins (e.g. insulin, epidermal growth factor and vascular 
endothelial growth factor receptors) [76, 77].
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Tumour-associated gangliosides have been suggested as a result of initial oncogenic 
transformation and play a key role in the induction of invasion and metastasis [75, 78]. 
Examples of gangliosides that are overexpressed in cancers are GD2 in neuroblastoma [79] 
and small cell lung cancer (SCLC) [80], GD3 in melanoma [81], GM2 [82] and fucosyl-GM1 
in SCLC [81].
 Figure 3. Biosynthesis of gangliosides.
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Some gangliosides overexpressed in cancers have been identified as adhesion molecules, which 
promote tumour cell metastasis. Gangliosides such as GD2, GD3 and GT1b form complexes 
with integrins [83] in melanoma where the terminal sialic acid residues of these gangliosides 
inhibit cell attachment by abrogating the interaction between integrin α5β1 and fibronectin [84]. 
Gangliosides on tumour cells also promote metastasis by forming aggregates with peripheral 
blood mononuclear cells (PBMCs) or platelets. This is due to the interaction between sialic acid 
moieties on gangliosides with sialic acid-binding proteins named Siglecs (sialic acid/immuno-
globulin/lectin) [85], which are expressed on various types of blood cells [86]. These tumour 
aggregates may induce the blood cells to release factors that activate endothelial cells to elicit 
cell adhesion molecules (ICAMs, VCAMs, E-selectin and P-selectin), which in turn initiate 
tumour cell adhesion or invasion [87, 88]. Siglec-7 has been reported to bind preferentially to 
sialyl-2→6 GalNAc [86]. Interestingly, GD3, GD2 and GT1b share the same sialyl2→6 GalNAc 
moiety [86], and they are overexpressed on a variety of tumours [89]. Thus, disialo epitopes may 
promote metastasis by binding to Siglecs expressed on blood cells.
In addition to the cell adhesion function, gangliosides have been reported to act as immune 
checkpoint molecules to aid in the escape of tumour cells from immune surveillance. 
Gangliosides released from the active secretion of tumour cells into serum can be taken up 
by T cells, with ensuing inhibition of T-cell proliferation and activation. The inhibitory action 
includes the defects in antigen presentation and reduction of cytokine [IFN-gamma (IFN-γ), 
interleukin-2 (IL-2) and IL-4] production [90–95]. The molecular mechanism of ganglioside-
induced T-cell dysfunction was suggested to involve the inhibition of NF-kappa B (NF-κB) 
activity of T cells via degradation of RelA/p50 dimer and p50/p50 homodimer proteins [96, 97].
4.3. Serum cancer biomarkers
Better survival rates among cancer patients are correlated with earlier detection. The utilisa-
tion of serum cancer biomarkers has played a major role in not only early detection of can-
cer but also prediction of cancer recurrence following initial therapy [98]. However, current 
clinically approved serum cancer biomarkers are characterised by low sensitivity in detect-
ing cancers [99]. Thus, the development of highly sensitive novel serum cancer biomarkers 
with better diagnostic and prognostic performance may enhance early detection rates and 
identification of new targets for anticancer therapy.
4.3.1. α-Fetoprotein (AFP)
α-Fetoprotein (AFP) is a 70 kDa glycoprotein [99], normally only secreted by foetal liver and 
present in foetal serum [100]. However, under certain pathological conditions, when it is pres-
ent in adult serum, AFP is associated with cancer. Thus, AFP has been used as a serological 
marker for the early diagnosis of hepatocellular carcinoma (HCC) [101] and non-seminoma-
tous germ cell tumours (NSGCT) [102].
AFP has a single N-linked oligosaccharide with a biantennary complex-type structure, with 
altered core fucosylation and terminal sialylation in HCC and NSGCT (Figure 4) [102]. 
Kobayashi et al. reported higher α-1,6-fucosyltransferase (FUT8) expression in HCC tis-
sues than non-cancerous tissues and increased in fucosylation were correlated with HCC 
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progression [101]. In addition to HCC, overexpression of FUT8 in thyroid carcinoma tissue 
has been linked directly to tumour size and lymph node metastasis [103]. In a study, Osumi 
and coworkers demonstrated that upregulated of FUT8 expression in cancer cell regulated 
the expression of E-cadherin. E-cadherin was responsible in the enhancement of cell-cell 
adhesion, which in turns contributes to the metastatic potential of cancer cells [104].
4.3.2. Prostate-specific antigen (PSA)
Prostate-specific antigen (PSA) is a 28.4 kDa glycoprotein with an N-linked glycosylation site. 
PSA has been used widely to screen for prostate cancer in men [99]. PSA is normally secreted 
by the prostate epithelium and periurethral glands. In prostate cancer, disruption of the pros-
tate epithelium leads to the release of PSA into serum [99]. When compared to PSA isolated 
from healthy individuals, PSA isolated from the serum of prostate cancer patients shown 
 Figure 4. The structures of the N-linked glycans expressed on AFP associated with HCC and NSGCT patients.
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significant higher levels of core-fucosylated biantennary glycans and α-(2,3)-linked sialic 
acids [105–109]. PSA is composed of several glycoforms [110, 111]. PSA with core-fucosylated 
biantennary glycans (FA2G2, FA2(6)G1S1 and FA2(6)BG1S1) and terminal α-(2,3)-linked sialic 
acids (A2 and A2G2) (Figure 5) were found elevated in prostate cancer patient serum [60].
4.3.3. Cancer antigen 19-9 (CA19-9)
Cancer antigen 19-9 (CA19-9) corresponds to a carbohydrate structure, sialyl-Lewis a (SLea) 
[99], which is overexpressed on cancer cell surface as a glycolipid and/or as an O-linked 
glycoprotein [112]. CA19-9 was first characterised by 1116-NS19-9 mAb [113] and has been 
found primarily in pancreatic and biliary tract cancers [113]. It has been used as a serum bio-
marker for pancreatic cancer [114]. In neoplastic tissues, epigenetic silencing of the gene for 
 Figure 5. N-linked oligosaccharide structures of PSA elevated in prostate cancer patient serum.
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α-(2,6)-sialyl transferase leads to the abnormal synthesis and accumulation of SLea, instead 
of its normal counterpart disialyl Lewis a (di-SLea). SLea has been reported to play a crucial 
role in cancer invasion/metastasis by acting as ligand for endothelial cell E-selectin, which is 
responsible for cell adhesion [115–118].
It is worth noting that majority of these glycobiomarkers were discovered by generating 
tumour-specific monoclonal antibodies (mAbs). In addition to aid in the discovery of addi-
tional carbohydrate-based biomarkers, these tumour-specific mAbs have great potential in 
treating neoplastic disease.
4.4. Antibody-based immunotherapy of cancer
Specific recognition and elimination of malignant cells by antibodies were proposed over a 
century ago [119]. The development of antibody-based therapies for cancer has been the focus 
of considerable interest for decades. Several criteria have been described for the selection of 
antitumour mAbs: (1) the mAb binds to cell surface tumour antigen, (2) the mAb binds to 
tumour antigen at high affinity, (3) the mAb recognises tumour antigen that is overexpressed 
on tumours but has limited expression on normal tissues, (4) the mAb has potent immune-
mediated and non-immune-mediated cytotoxicity effects, (5) the mAb directly kills tumour 
cells and/or (6) the mAb internalises into target cells so it can delivery toxic payloads. To date, 
many therapeutic monoclonal antibodies (mAbs) have been developed, mostly against pro-
tein antigens, and have proven useful in cancer therapy.
4.5. Anti-glycan monoclonal antibody against cancer
Anti-glycan mAbs have also found usage in clinical applications. Dinutuximab is a chimeric 
mAb directed against GD2 on neuroblastoma and induced cell lysis via Antibody dependent 
cellular cytotoxicity (ADCC) and Complement dependent cytotoxicity (CDC) (http://www.
fda.gov/). It was approved by FDA in 2015, for use in high-risk neuroblastoma paediatric 
patients, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), 
interleukin-2 (IL-2) and 13-cis-retinoic acid (RA). GD2 is a disialoganglioside overexpressed 
on neuroblastoma and melanoma [79, 120] with limited expression on normal neurons in the 
cerebellum, skin melanocytes and peripheral nerves [121], making it well suited as target for 
cancer therapy. The FDA approval was based on the findings from a phase III trial, focused 
on 226 children with high-risk neuroblastoma who had responded to initial treatment [122]. 
Patients were enrolled to receive either Dinutuximab associated with IL-12, GM-CSF and RA 
or RA alone, after having responded to the first-line treatment. Three years after treatment 
assignment, patients received Dinutuximab combination showed superior rates of event-free 
survival and overall survival when compared to standard therapy.
BR96 is an anti-Ley mAb. It was shown to induce direct tumour cell death to Ley-positive 
tumour cell lines in addition to ADCC or CDC [123]. In a phase I trial, BR96-doxorubicin 
immunoconjugates showed limited clinical antitumour activity with patients experiencing a 
clinically significant hypersensitivity reaction to the mouse man [124]. BR96 was conjugated 
to doxorubicin and docetaxel (also known as SGN-15), and 62 advanced non-small-cell lung 
cancer patients were treated in a randomised Phase II trial. An increased in survival was 
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reported for patients receiving SGN-15 when compared with patients receiving doxorubicin 
and docetaxel alone [125]. hu3S193 is a humanised anti-Ley mab. It contains only 3–5% of 
murine residues in the antibody variable domain, conferring a low risk of hypersensitivity 
responses. In a MCF-7 xenograft preventive model, hu3S193 managed to significantly slow 
tumour growth compared with placebo and isotype-matched control IgG1 antibody [126]. In 
a phase I trial in 15 cancer patients (six breast, eight colorectal and one non-small-cell lung 
cancers), hu3S193 showed only minimal toxicity. The biodistribution of indium 111 radio-
labeled hu3S193 ((111)In-hu3S193) showed no evidence of normal tissue uptake, but (111)
In-hu3S193 uptake was seen in cutaneous, lymph node and hepatic metastases [127].
KM231 is a murine mAb recognising SLea. KM231 was observed to react with many human 
gastrointestinal cancer tissues and could detect shed antigen in the sera of cancer patients. 
Shitara et al. made KM231-ricin A chain immunotoxin to evaluate the tumoricidal effect of 
KM231 on ascites and subcutaneous xenograft tumours growing in nude mice. KM231 signifi-
cantly inhibited the growth of established subcutaneous tumours. This result suggested that 
it was an effective tumoricidal drug when it was conjugated to cytotoxic reagents [128]. 5B1 
(IgG1) and 7E3 (IgM) are other anti-SLea mAbs generated by immunising mice with SLea-KLH 
vaccine. Both mAbs are very potent in inducing CDC. Moreover, 5B1 is also highly active in 
inducing ADCC [129].
NCCT-ST-421 (IgG3) is a murine mAb raised by immunising mice with human gastric cancer 
xenograft (ST-4). The mAb recognises dimeric Lea epitope and cross reacts with simple Lea 
and extended Lea epitopes. NCCT-ST-421 induced ADCC and CDC to antigen-positive cells. 
It was shown to induce direct cell death as well through apoptotic mechanism. Although 
NCCT-ST-421 showed promising antitumour responses, no further details regarding clinical 
studies were described.
4.6. Direct killing anti-glycan monoclonal antibody
Oncosis is a progressive cell death process initially involving the impairment of ionic pumps 
of the cell membrane accompanied by cellular and organelle swelling. Subsequently, a gradu-
ally increase in membrane permeability due to an increasing cytosolic calcium concentration 
as well as rearrangement of cytoskeletal proteins results in pore formation in the cell mem-
brane [130, 131]. It has been well accepted that tumours are able to manipulate the tumour 
microenvironment by releasing cytokines and other soluble factors, which create an immuno-
suppressive environment [132]. Release of cellular content into immunosuppressive tumour 
microenvironment via mAb-induced pore formation during oncosis may help in evoking 
immune responses via the release of danger-associated molecular patterns (‘DAMPs’; [133]).
FG88 (FG88.2 and FG88.7) are internalising murine IgG3 mAbs recognise Lea-c-x glycans 
(Figure 6) overexpressed on a wide range of tumour cells and tissues at subnanomolar 
potency [134]. The FG88.2 mAb showed excellent tumour cell surface antigen binding and 
good levels of binding to a large percentage of tumours with low level binding to a limited 
number of normal tissues by immunohistochemistry. The significant association of strong 
FG88.2 binding with poor outcome in the colorectal sample cohort, independent of stage and 
vascular invasion, suggests that FG88.2 mAb has great potential targeting the most aggressive 
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colorectal cancers. FG88 mAbs induce potent ADCC, CDC and direct killing of tumour cells 
via oncosis. In the in vivo xenograft study, FG88 mAbs eradicated both primary and meta-
static tumours. By releasing tumour cellular contents via mAb-induced pores, the FG88 mAbs 
might also be able to reverse the immunosuppressive tumour microenvironment leading to 
effective presentation of multiple epitopes from the lysed tumour cells and amplifying the 
antitumour immune response.
Several other anti-glycan mAbs can also induce similar direct tumour killing to FG88. MAb 
84, when bound to human embryonic stem cells, induced cytoskeletal protein (α-actinin, 
paxillin and talin) degradation, which in turned increased the mobility of the plasma 
membrane, resulting in the clustering of antigens on the cell surface. Following antigen 
clustering, formation of pores through the plasma membrane resulted in oncosis [135]. 
N-glycolylneuraminic acid (NeuGc) is a sialic acid variant of N-acetylneuraminic acid 
(NeuAc). Humans cannot synthesise NeuGc because they lack the enzyme cytidine mono-
phospho-N-acetylneuraminic acid hydroxylase (CMAH), responsible for its biosynthesis. 
 Figure 6. Details of glycan binding by FG88 mAbs.
Monoclonal Antibodies Against Tumour-Associated Carbohydrate Antigens
http://dx.doi.org/10.5772/66996
49
However, recent evidence suggests that NeuGc can be incorporated into human glycan from 
dietary sources. More interestingly, although not fully understood, human tumours actively 
incorporate NeuGc at a much higher rate than normal primary cells. As such, it is highly 
expressed in several human cancer cells [136], making it an appealing target for immuno-
therapy. It is noteworthy that natural circulating antibodies to NeuGc can be detected in 
normal human serum and that these antibodies have been shown to induce complement-
dependent cell lysis [137]. Anti-NGcGM3 14 F7 mAb induced rapid cell death which was 
accompanied by cellular swelling, membrane lesion formation and cytoskeleton activation 
and cell aggregation. Moreover, no evidences of DNA fragmentation, chromatin modifica-
tion or caspase activation were found. But 14 F7-treated cells showed large lesions at the 
plasma membrane, much bigger pores created by complement, perforin or bacterial toxins, 
suggesting an oncosis-like phenomenon [138]. Currently, the NeuGc-ganglioside anti-idio-
typic mAb, Racotumomab (1E10), is under development. By molecular mimicry, a selected 
anti-idiotypic mAb will behave like the original antigen. In a phase III randomised trial in 
non-small-cell lung cancer, Racotumomab conferred a significant survival advantage [139] 
and induced anti-NeuGc antibodies capable of killing tumour cells by a mechanism similar 
to oncosis, validating the approach and highlighting the beneficial value of antibodies medi-
ating oncosis for therapeutic purposes [140].
5. Conclusion
Glycoconjugates are major components of cells. They are involved in defining and modulating 
multiple key physiological processes in normal tissues. Aberrant glycosylation in cancer lead 
to the modification of glycosylations, resulted in the generation of TACAs, which drive several 
biological processes in cancer. Investigation of the molecular basis underlying these glycan 
modifications will aid in the understanding of cancer immunology as well as the development 
of anti-glycan therapeutic mAbs. Furthermore, rapid advances in glycomics and glycopro-
teomics will have a major impact on the unravelling of novel targets for cancer treatment.
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